» Articles » PMID: 25958848

The Relationship Between the High-density Lipoprotein (HDL)-associated Sphingosine-1-phosphate (S1P) and Coronary In-stent Restenosis

Overview
Journal Clin Chim Acta
Specialty Biochemistry
Date 2015 May 12
PMID 25958848
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background: High-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P) contributed to several beneficial effects in the cardiovascular system. We explored the relationship between the HDL-S1P concentrations and coronary in-stent restenosis (ISR).

Methods: Fifty consecutive patients with ISR and 50 normal control subjects were included. The serum S1P, HDL-S1P and clinical data were collected to explore the relationships between these parameters and ISR.

Results: The patients with ISR had significantly lower concentrations of serum S1P (96.10 ± 26.33 vs. 113.40 ± 32.72; P = 0.004) and HDL-S1P (32.81 ± 10.02 vs. 42.72 ± 11.75; P < 0.001). All included patients were divided into four quartiles based on their concentrations of HDL-S1P: Quartile 1 (18.63-28.51 ng/ml), Quartile 2 (28.62-37.28 ng/ml), Quartile 3 (37.35-45.27 ng/ml), and Quartile 4 (45.59-79.36 ng/ml). The rates of ISR were 84%, 48%, 40% and 28%, respectively. The patients in Quartile 1 exhibited significantly higher rates of ISR compared with the other groups (P = 0.001). A multivariate stepwise logistic regression analysis indicated that HDL-S1P (OR = 0.846, 95% CI = 0.767-0.932, P = 0.001) was an independent predictor of ISR. An ROC analysis indicated that HDL-S1P = 30.37 ng/ml and had a 90% sensitivity and a 52% specificity in predicting ISR.

Conclusions: HDL-S1P is an independent predictor of ISR, and patients with higher concentrations of HDL-S1P have a low risk of ISR.

Citing Articles

The emerging roles of sphingosine 1-phosphate and SphK1 in cancer resistance: a promising therapeutic target.

Sami Alkafaas S, Elsalahaty M, Ismail D, Ali Radwan M, Samy ElKafas S, Loutfy S Cancer Cell Int. 2024; 24(1):89.

PMID: 38419070 PMC: 10903003. DOI: 10.1186/s12935-024-03221-8.


HDL and Lipid Metabolism.

Zhang Q, Ke Y, Hong H Adv Exp Med Biol. 2022; 1377:49-61.

PMID: 35575920 DOI: 10.1007/978-981-19-1592-5_4.


Fetal High-Density Lipoproteins: Current Knowledge on Particle Metabolism, Composition and Function in Health and Disease.

Stadler J, Wadsack C, Marsche G Biomedicines. 2021; 9(4).

PMID: 33808220 PMC: 8067099. DOI: 10.3390/biomedicines9040349.


Lysolipids in Vascular Development, Biology, and Disease.

Engelbrecht E, MacRae C, Hla T Arterioscler Thromb Vasc Biol. 2020; 41(2):564-584.

PMID: 33327749 PMC: 8105276. DOI: 10.1161/ATVBAHA.120.305565.


Endothelial-protective effects of a G-protein-biased sphingosine-1 phosphate receptor-1 agonist, SAR247799, in type-2 diabetes rats and a randomized placebo-controlled patient trial.

Bergougnan L, Andersen G, Plum-Morschel L, Evaristi M, Poirier B, Tardat A Br J Clin Pharmacol. 2020; 87(5):2303-2320.

PMID: 33125753 PMC: 8247405. DOI: 10.1111/bcp.14632.